A Phase 2 interventional study of pridopidine in Huntington Disease, sponsored by Prilenia. Completed. Per ClinicalTrials.gov, last updated 2022-02-09.
Sponsored by Prilenia · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Huntington disease (HD) is a hereditary neurodegenerative disorder causing impairment in movement, behavioral dysfunction and dementia. The movement disorder is mainly characterized by chorea (involuntary movements) and a progressive loss of voluntary movement causing a substantial functional impairment over time. The study will assess the long-term safety of pridopidine and the treatment effects during long-term, open-label treatment.
293 studies on the registry are indexed under Huntington Disease; 54 are open to participants now.
This study's enrollment of 134 is above the median of 40 across 207 interventional studies indexed under Huntington Disease.
Browse Huntington Disease studies →Prilenia is the lead sponsor of 9 studies on the registry; 2 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 5 (100%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patient has the ability to transition from in-person study visits to virtual study visits. The first remote visit (RV1) will take place within approximately 30 days after the last in-person visit.
Exclusion Criteria:
Known allergy to any ingredients of the trial medication.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
45mg bid
Drug: pridopidine
45mg bid
Number of Patients With at Least One Adverse Event
Time frame: From signing of the informed consent through the end of the follow-up period, which was defined as 30 days after the final study visit in an individual patient, an average of 2.8 years
Unified Huntington's Disease Rating Scale (UHDRS) Total Motor Score (TMS)
TMS was defined as the sum of all UHDRS motor domains ratings. The motor section of the UHDRS assesses motor features of Huntington's Disease (HD) with standardized ratings of oculo-motor function, dysarthria, chorea, dystonia, gait, and postural stability. Each of 31 assessments is rated on a scale of 0 (normal) to 4 (marked impairment) for a TMS range of 0-124.
Time frame: Baseline and at Month 12, 24, 36, 48, 60, and 72
The study recruited adult patients with Huntington's Disease (HD) who had completed studies ACR16C009 (NCT00724048) or TV7820-CNS-20002 (NCT02006472). The first patient was recruited on 24 Mar 2011, and the last patient completed the trial on 5 Jan 2018.
| Milestone | Pridopidine |
|---|---|
| Started | 134 |
| Completed | 40 |
| Not completed | 94 |
| Withdrew: Withdrawal by subject | 23 |
| Withdrew: Adverse event | 21 |
| Withdrew: Physician decision | 13 |
| Withdrew: Death | 8 |
| Withdrew: Withdrawal by parent/guardian | 5 |
| Withdrew: Protocol violation | 3 |
| Withdrew: Non-compliance with study drug | 2 |
| Withdrew: Lost to follow-up | 2 |
| Withdrew: Various | 17 |
| Participants | Pridopidine |
|---|---|
| Number of Patients With at Least One Adverse Event | 119 |
TMS was defined as the sum of all UHDRS motor domains ratings. The motor section of the UHDRS assesses motor features of Huntington's Disease (HD) with standardized ratings of oculo-motor function, dysarthria, chorea, dystonia, gait, and postural stability. Each of 31 assessments is rated on a scale of 0 (normal) to 4 (marked impairment) for a TMS range of 0-124.
| score on a scale | Pridopidine |
|---|---|
| Baseline | 38.3 ± 15.2 |
| Month 12 | 41.5 ± 18.7 |
| Month 24 | 41.7 ± 20.7 |
| Month 36 | 44.7 ± 19.8 |
| Month 48 | 45.3 ± 19.7 |
| Month 60 | 45.7 ± 20.6 |
| Month 72 | 50.0 ± 23.2 |
Collected over From signing of the informed consent through the end of the follow-up period, which was defined as 30 days after the final study visit in an individual patient, an average of 2.8 years. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pridopidine | 8/134 (6%) | 31/134 (23.1%) | 119/134 (88.8%) |
| Event | Pridopidine |
|---|---|
| FallInjury, poisoning and procedural complications | 4/134 |
| Subdural haematomaInjury, poisoning and procedural complications | 4/134 |
| Pneumonia aspirationRespiratory, thoracic and mediastinal disorders | 3/134 |
| DysphagiaGastrointestinal disorders | 2/134 |
| Skull fractureInjury, poisoning and procedural complications | 2/134 |
| ConvulsionNervous system disorders | 2/134 |
| Loss of consciousnessNervous system disorders | 2/134 |
| Subarachnoid haemorrhageNervous system disorders | 2/134 |
| AgitationPsychiatric disorders | 2/134 |
| DepressionPsychiatric disorders | 2/134 |
| Event | Pridopidine |
|---|---|
| FallInjury, poisoning and procedural complications | 46/134 |
| Weight decreasedInvestigations | 30/134 |
| AnxietyPsychiatric disorders | 27/134 |
| InsomniaPsychiatric disorders | 24/134 |
| DepressionPsychiatric disorders | 20/134 |
| ContusionInjury, poisoning and procedural complications | 18/134 |
| LacerationInjury, poisoning and procedural complications | 18/134 |
| ChoreaNervous system disorders | 18/134 |
| DiarrhoeaGastrointestinal disorders | 16/134 |
| NasopharyngitisInfections and infestations | 16/134 |
| Age, Continuous(years) | Pridopidine |
|---|---|
| Mean | 52.4 ± 9.98 |
| Sex: Female, Male(Participants) | Pridopidine |
|---|---|
| Female | 67 |
| Male | 67 |
| Race (NIH/OMB)(Participants) | Pridopidine |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 3 |
| White | 129 |
| More than one race | 0 |
| Unknown or Not Reported | 2 |
| Region of Enrollment(participants) | Pridopidine |
|---|---|
| Canada | 50 |
| United States | 84 |
| Weight(kg) | Pridopidine |
|---|---|
| Mean | 74.7 ± 18.6 |
No study locations are listed for this record.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2011 to primary completion in Jan 2018, 81 months.
Results were first posted in Feb 2022, 4 years 1 month after primary completion.
Of 22 phase 2 interventional studies under Huntington Disease, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 40. This study's 81 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pridopidine
Prilenia